single10MG
PT-141
10MG Protocol
PT-141 10MG
Injection Freq.
Inject once daily
Cycle Sched.
Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired)
Reconstitution
3.0 mL BAC water
Improved sexual-desire and reduced distress scores in clinical trials (HSDD)
Potential improvements in erectile responses (early studies)
Increased arousal measures reported in research
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–8 | 500 mcg (0.5 mg) | 15 |
| 2 | Weeks 9–12 | 1000 mcg (1.0 mg) | 30 |
| 3 | Weeks 13–16 | 1500 mcg (1.5 mg) | 45 |
Inject once daily
Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired)
PT-141 (bremelanotide) is described as a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, with emphasis on MC3R and MC4R activity. The protocol explains that MC4R activation in the central nervous system increases dopamine signaling in reward and arousal regions (including the nucleus accumbens and medial preoptic area), which is linked to increased sexual motivation and desire. Unlike PDE5 inhibitors, PT-141 does not primarily act by directly amplifying nitric oxide signaling; in men, erectile effects are described as secondary to central arousal pathways that then influence peripheral physiology. The page also attributes certain adverse effects to peripheral melanocortin activity—particularly MC1R agonism—such as transient blood-pressure increases and possible skin hyperpigmentation with repeated exposure. In summary, PT-141 is positioned as a centrally acting desire/arousal modulator via melanocortin–dopamine pathways.
Nausea
Flushing
Headache
Injection-site reactions
Transient blood-pressure increases
Skin darkening / hyperpigmentation (generally reversible)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)